| 肖婷婷,邓坦.原发性肝癌合并门静脉癌栓治疗进展[J].安徽医药,2025,29(3):460-466. |
| 原发性肝癌合并门静脉癌栓治疗进展 |
| Progress in the treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis |
| |
| DOI：10.3969/j.issn.1009-6469.2025.03.008 |
| 中文关键词: 原发性肝癌 门静脉癌栓 肝切除术 仑伐替尼 纳武利尤单抗 综述 |
| 英文关键词: Hepatocellular carcinoma Portal vein tumor thrombosis Hepatectomy Lenvatinib Nivolumab Review |
| 基金项目: |
|
| 摘要点击次数: 494 |
| 全文下载次数: 234 |
| 中文摘要: |
| 原发性肝癌的晚期病人有 60%~90%合并门静脉癌栓，目前大多数病人面临临床疗效欠佳、预后差等问题。索拉非尼作为原发性肝癌合并门静脉癌栓病人多年来的一线治疗方案，在临床应用中疗效欠佳。近年来，手术、靶向治疗、免疫治疗等治疗手段在改善病人预后方面有较好的疗效。该研究就原发性肝癌合并门静脉癌栓的现状和治疗进展进行综述。 |
| 英文摘要: |
| Of advanced patients with hepatocellular carcinoma, 60% to 90% are complicated with portal vein tumor thrombosis. Cur-rently, most patients are faced with poor clinical efficacy and poor prognosis. Sorafenib has been the first-line therapy for the patientsfor many years, but the clinical efficacy is not satisfying. In recent years, surgery, targeted therapy, immunotherapy and other therapeu-tic means have a good effect on improving the prognosis of patients. This article reviews the current status and treatment progress of he-patocellular carcinoma with portal vein tumor thrombosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
